Friday, September 16, 2016

Optiray 320


See also: Generic Optiray 240, Generic Optiray 300, Generic Optiray 350


Optiray 320 is a brand name of ioversol, approved by the FDA in the following formulation(s):


OPTIRAY 320 (ioversol - injectable; injection)



  • Manufacturer: MALLINCKRODT

    Approval date: December 30, 1988

    Strength(s): 68% [RLD]

Has a generic version of Optiray 320 been approved?


No. There is currently no therapeutically equivalent version of Optiray 320 available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Optiray 320. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Optiray 320.

See also...

  • Optiray 320 Consumer Information (Cerner Multum)
  • Ioversol Consumer Information (Cerner Multum)
Posted by at No comments:
Labels:

Humatrope


Humatrope is a brand name of somatropin, approved by the FDA in the following formulation(s):


HUMATROPE (somatropin recombinant - injectable; injection)



  • Manufacturer: LILLY

    Approval date: February 4, 1999

    Strength(s): 12MG/VIAL [RLD], 24MG/VIAL [RLD]

Has a generic version of Humatrope been approved?


No. There is currently no therapeutically equivalent version of Humatrope available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humatrope. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Humatrope.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 12, 2012 - TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS

    • November 1, 2013 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Humatrope Cartridge Consumer Information (Wolters Kluwer)
  • Humatrope Vial Consumer Information (Wolters Kluwer)
  • Humatrope Consumer Information (Cerner Multum)
  • Humatrope Advanced Consumer Information (Micromedex)
  • Somatropin (rDNA origin - Nonrefrigerated) Consumer Information (Wolters Kluwer)
  • Somatropin (rDNA origin - Refrigerated) Consumer Information (Wolters Kluwer)
  • Somatropin (rDNA origin - Refrigerated) Cartridge Consumer Information (Wolters Kluwer)
  • Somatropin (rDNA origin - Refrigerated) Vial Consumer Information (Wolters Kluwer)
  • Somatropin (rDNA origin - Refrigerated) Vials Consumer Information (Wolters Kluwer)
  • Somatropin Consumer Information (Cerner Multum)
  • Somatropin, e-coli derived Subcutaneous, Injection Advanced Consumer Information (Micromedex)
  • Somatropin, mammalian derived Subcutaneous, Injection Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Humalog Mix 75 / 25


See also: Generic Humalog Mix 50/50, Generic Humalog Mix 50/50 KwikPen, Generic Humalog Mix 50/50 Pen, Generic Humalog Mix 75/25 KwikPen, Generic Humalog Mix 75/25 Pen


Humalog Mix 75/25 is a brand name of insulin lispro/insulin lispro protamine, approved by the FDA in the following formulation(s):


HUMALOG MIX 75/25 (insulin lispro protamine recombinant; insulin lispro recombinant - injectable; injection)



  • Manufacturer: LILLY

    Approval date: December 22, 1999

    Strength(s): 75 UNITS/ML;25 UNITS/ML [RLD]

Has a generic version of Humalog Mix 75/25 been approved?


No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Monomeric insulin analog formulations
    Patent 5,461,031
    Issued: October 24, 1995
    Inventor(s): De Felippis; Michael R.
    Assignee(s): Eli Lilly and Company
    The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
    Patent expiration dates:

    • June 16, 2014




  • Insulin analog formulations
    Patent 5,474,978
    Issued: December 12, 1995
    Inventor(s): Bakaysa; Diane L. & Brems; David N. & Frank; Bruce H. & Havel; Henry A. & Pekar; Allen H.
    Assignee(s): Eli Lilly and Company
    The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
    Patent expiration dates:

    • June 16, 2014




  • Insulin analogs modified at position 29 of the B chain
    Patent 5,514,646
    Issued: May 7, 1996
    Inventor(s): Chance; Ronald E. & DiMarchi; Richard D. & Frank; Bruce H. & Shields; James E.
    Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
    Patent expiration dates:

    • May 7, 2013




  • Monomeric insulin analog formulations
    Patent 5,747,642
    Issued: May 5, 1998
    Inventor(s): De Felippis; Michael R.
    Assignee(s): Eli Lilly and Company
    The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
    Patent expiration dates:

    • June 16, 2014



See also...

  • HumaLog Mix 75/25 Vials Consumer Information (Wolters Kluwer)
  • Humalog Mix 75/25 Pens Consumer Information (Wolters Kluwer)
  • Humalog Mix 75/25 Consumer Information (Cerner Multum)
  • Humalog Mix 75/25 Advanced Consumer Information (Micromedex)
  • Humalog Mix Consumer Information (Drugs.com)
  • Insulin Lispro Protamine/Insulin Lispro Pens Consumer Information (Wolters Kluwer)
  • Insulin Lispro Protamine/Insulin Lispro Vials Consumer Information (Wolters Kluwer)
  • Insulin lispro and insulin lispro protamine Consumer Information (Cerner Multum)
  • Insulin lispro protamine and insulin lispro Subcutaneous Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Humalog Mix 75 / 25 Pen


See also: Generic Humalog Mix 50/50, Generic Humalog Mix 50/50 KwikPen, Generic Humalog Mix 50/50 Pen, Generic Humalog Mix 75/25, Generic Humalog Mix 75/25 KwikPen


Humalog Mix 75/25 Pen is a brand name of insulin lispro/insulin lispro protamine, approved by the FDA in the following formulation(s):


HUMALOG MIX 75/25 PEN (insulin lispro protamine recombinant; insulin lispro recombinant - injectable; injection)



  • Manufacturer: LILLY

    Approval date: December 22, 1999

    Strength(s): 75 UNITS/ML;25 UNITS/ML [RLD]

Has a generic version of Humalog Mix 75/25 Pen been approved?


No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 Pen available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25 Pen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Humalog Mix 75/25 Pen.

See also...

  • Humalog Mix 75/25 Pen Consumer Information (Cerner Multum)
  • Humalog Mix Consumer Information (Drugs.com)
  • Insulin Lispro Protamine/Insulin Lispro Pens Consumer Information (Wolters Kluwer)
  • Insulin Lispro Protamine/Insulin Lispro Vials Consumer Information (Wolters Kluwer)
  • Insulin lispro and insulin lispro protamine Consumer Information (Cerner Multum)
  • Insulin lispro protamine and insulin lispro Subcutaneous Advanced Consumer Information (Micromedex)
Posted by at No comments:
Labels:

Antivert


Antivert is a brand name of meclizine, approved by the FDA in the following formulation(s):


ANTIVERT (meclizine hydrochloride - tablet; oral)



  • Manufacturer: PFIZER

    Approved Prior to Jan 1, 1982

    Strength(s): 12.5MG [RLD][AA], 25MG [RLD][AA]


  • Manufacturer: PFIZER

    Approval date: January 20, 1982

    Strength(s): 50MG [RLD][AA]

Has a generic version of Antivert been approved?


Yes. The following products are equivalent to Antivert:


meclizine hydrochloride tablet; oral



  • Manufacturer: AMNEAL PHARMS

    Approval date: February 23, 2011

    Strength(s): 12.5MG [AA], 25MG [AA], 50MG [AA]


  • Manufacturer: JUBILANT CADISTA

    Approval date: June 4, 2010

    Strength(s): 12.5MG [AA], 25MG [AA]


  • Manufacturer: PAR PHARM

    Approved Prior to Jan 1, 1982

    Strength(s): 12.5MG [AA], 25MG [AA]


  • Manufacturer: PAR PHARM

    Approval date: March 31, 1988

    Strength(s): 50MG [AA]


  • Manufacturer: SANDOZ

    Approval date: May 22, 1989

    Strength(s): 12.5MG [AA], 25MG [AA]


  • Manufacturer: VINTAGE PHARMS

    Approval date: January 30, 1997

    Strength(s): 12.5MG [AA], 25MG [AA]


  • Manufacturer: WATSON LABS

    Approved Prior to Jan 1, 1982

    Strength(s): 25MG [AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Antivert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Antivert.

See also...

  • Antivert Consumer Information (Drugs.com)
  • Antivert Consumer Information (Wolters Kluwer)
  • Antivert Consumer Information (Cerner Multum)
  • Meclizine Consumer Information (Drugs.com)
  • Meclizine Consumer Information (Wolters Kluwer)
  • Meclizine Chewable Tablets Consumer Information (Wolters Kluwer)
  • Meclizine Consumer Information (Cerner Multum)
  • Meclizine Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Allegra


Allegra is a brand name of fexofenadine, approved by the FDA in the following formulation(s):


ALLEGRA (fexofenadine hydrochloride - suspension; oral)



  • Manufacturer: SANOFI AVENTIS US

    Approval date: October 16, 2006

    Strength(s): 30MG/5ML [RLD]

Has a generic version of Allegra been approved?


No. There is currently no therapeutically equivalent version of Allegra available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Allegra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Piperidine derivatives
    Patent 5,578,610
    Issued: November 26, 1996
    Inventor(s): D'Ambra; Thomas E.
    Assignee(s): Albany Molecular Research, Inc.
    The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
    Patent expiration dates:

    • November 26, 2013
      ✓ 
      Patent use: USE IN TREATING ALLERGIC REACTIONS


    • November 26, 2013
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • May 26, 2014
      ✓ 
      Patent use: USE IN TREATING ALLERGIC REACTIONS
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 5,738,872
    Issued: April 14, 1998
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marquerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:

    • February 28, 2015


    • August 28, 2015
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical compositions for piperidinalkanol compounds
    Patent 5,855,912
    Issued: January 5, 1999
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:

    • February 28, 2015


    • August 28, 2015
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 5,932,247
    Issued: August 3, 1999
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:

    • February 28, 2015


    • August 28, 2015
      ✓ 
      Pediatric exclusivity




  • Method of providing an antihistaminic effect in a hepatically impaired patient
    Patent 6,037,353
    Issued: March 14, 2000
    Inventor(s): Woodward; James K. & Okerholm; Richard A. & Eller; Mark G. & McNutt; Bruce E.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
    Patent expiration dates:

    • March 14, 2017
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS


    • March 14, 2017
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS


    • September 14, 2017
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 6,113,942
    Issued: September 5, 2000
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Aventis Pharmaceuticals Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:

    • February 28, 2015


    • August 28, 2015
      ✓ 
      Pediatric exclusivity




  • Method of providing an antihistaminic effect in a hepatically impaired patient
    Patent 6,187,791
    Issued: February 13, 2001
    Inventor(s): Woodward; James K. & Okerholm; Richard A. & Eller; Mark G. & McNutt; Bruce E.
    Assignee(s): Merrell Pharmaceuticals Inc.
    The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
    Patent expiration dates:

    • May 11, 2012
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS


    • May 11, 2012
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS


    • November 11, 2012
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS
      ✓ 
      Pediatric exclusivity




  • Method of providing an antihistaminic effect in a hepatically impaired patient
    Patent 6,399,632
    Issued: June 4, 2002
    Inventor(s): James K.; Woodward & Richard A.; Okerholm & Mark G.; Eller & Bruce E.; McNutt
    Assignee(s): Merrell Pharmaceuticals Inc.
    The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; n is an integer of from 1 to 5; R3 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
    Patent expiration dates:

    • May 11, 2012
      ✓ 
      Patent use: METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS


    • May 11, 2012
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS


    • November 11, 2012
      ✓ 
      Patent use: METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
      ✓ 
      Pediatric exclusivity




  • Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
    Patent 7,135,571
    Issued: November 14, 2006
    Inventor(s): Henton; Daniel R & McCarty; Frederick J & Tripp; Susan I & DeWitt; Jill E
    Assignee(s): Aventis Pharmaceuticals, Inc.
    The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulas which are useful as antihistamines, antiallergic agents and bronchodilators.
    Patent expiration dates:

    • May 18, 2014
      ✓ 
      Drug substance


    • November 18, 2014
      ✓ 
      Pediatric exclusivity




  • Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
    Patent 7,138,524
    Issued: November 21, 2006
    Inventor(s): McCarty; Frederick J. & Carr; Albert A.
    Assignee(s): Aventis Pharmaceuticals, Inc.
    The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulas which are useful as antihistamines, antiallergic agents and bronchodilators.
    Patent expiration dates:

    • May 18, 2014
      ✓ 
      Drug substance


    • November 18, 2014
      ✓ 
      Pediatric exclusivity



See also...

  • Allegra Consumer Information (Drugs.com)
  • Allegra Consumer Information (Wolters Kluwer)
  • Allegra Suspension Consumer Information (Wolters Kluwer)
  • Allegra Consumer Information (Cerner Multum)
  • Allegra Advanced Consumer Information (Micromedex)
  • Allegra AHFS DI Monographs (ASHP)
  • Fexofenadine Consumer Information (Wolters Kluwer)
  • Fexofenadine Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Fexofenadine Suspension Consumer Information (Wolters Kluwer)
  • Fexofenadine Consumer Information (Cerner Multum)
  • Fexofenadine Advanced Consumer Information (Micromedex)
  • Fexofenadine Hydrochloride AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Minirin


Minirin is a brand name of desmopressin, approved by the FDA in the following formulation(s):


MINIRIN (desmopressin acetate - spray, metered; nasal)



  • Manufacturer: FERRING

    Approval date: September 16, 2002

    Strength(s): 0.01MG/SPRAY [RLD][AB]

Has a generic version of Minirin been approved?


Yes. The following products are equivalent to Minirin:


DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) (desmopressin acetate spray, metered; nasal)



  • Manufacturer: APOTEX INC

    Approval date: January 27, 2005

    Strength(s): 0.01MG/SPRAY [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Minirin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Minirin.

See also...

  • Minirin Spray Consumer Information (Wolters Kluwer)
  • Minirin Advanced Consumer Information (Micromedex)
  • Desmopressin Consumer Information (Wolters Kluwer)
  • Desmopressin Solution Consumer Information (Wolters Kluwer)
  • Desmopressin Spray Consumer Information (Wolters Kluwer)
  • Desmopressin Tube Consumer Information (Wolters Kluwer)
  • Desmopressin Consumer Information (Cerner Multum)
  • Desmopressin injection Consumer Information (Cerner Multum)
  • Desmopressin nasal Consumer Information (Cerner Multum)
  • Desmopressin Nasal, Oral, Injection Advanced Consumer Information (Micromedex)
  • Desmopressin Acetate AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)